Benefits of positron emission tomography scans for the evaluation of radiotherapy

Intérêt de la tomographie par émission de positrons pour l’évaluation de la radiothérapie

P. Decazes (1, 2) , S. Thureau (2) , R. Modzelewski (2, 1) , M. Damilleville-Martin (3, 4) , P. Bohn (1, 2) , P. Vera (2, 1)

1 Service de médecine nucléaire [Rouen]
2 QuantIF-LITIS - Equipe Quantification en Imagerie Fonctionnelle
3 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
4 Département de radiothérapie et de physique médicale

The assessment of tumour response during and after radiotherapy determines the subsequent management of patients (adaptation of treatment plan, monitoring, adjuvant treatment, rescue treatment or palliative care). In addition to its role in extension assessment and therapeutic planning, positron emission tomography combined with computed tomography provides useful functional information for the evaluation of tumour response. The objective of this article is to review published data on positron emission tomography combined with computed tomography as a tool for evaluating external radiotherapy for cancers. Data on positron emission tomography combined with computed tomography scans acquired at different times (during, after initial and after definitive [chemo-]radiotherapy, during post-treatment follow-up) in solid tumours (lung, head and neck, cervix, oesophagus, prostate and rectum) were collected and analysed. Recent recommendations of the National Comprehensive Cancer Network are also reported. Positron emission tomography combined with computed tomography with (18F)-labelled fluorodeoxyglucose has a well-established role in clinical routine after chemoradiotherapy for locally advanced head and neck cancers, particularly to limit the number of neck lymph node dissection. This imaging modality also has a place for the evaluation of initial chemoradiotherapy of oesophageal cancer, including the detection of distant metastases, and for the post-therapeutic evaluation of cervical cancer. Several radiotracers for positron emission tomography combined with computed tomography, such as choline, are also recommended for patients with prostate cancer with biochemical failure. (18F)-fluorodeoxyglucose positron emission tomography combined with computed tomography is optional in many other circumstances and its clinical benefits, possibly in combination with MRI, to assess response to radiotherapy remain a very active area of research.

Mots clés: Monitoring; Positron emission tomography; Radiotherapy; Radiothérapie; Réponse thérapeutique; Suivi; Therapeutic response; Tomographie par émission de positons

Domaines: Sciences du Vivant [q-bio]

P. Decazes, S. Thureau, R. Modzelewski, M. Damilleville-Martin, P. Bohn, et al.. Benefits of positron emission tomography scans for the evaluation of radiotherapy. Cancer/Radiothérapie, 2020, 24 (5), pp.388-397. ⟨10.1016/j.canrad.2020.02.007⟩. ⟨hal-02922525⟩